Aslan Fred sold $690K of ARTV
Aslan Fred (Chief Executive Officer) sold 61,888 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 ($0.69M total) on 2026-09-03.
How this was made
The 30-second read
Why it matters
The Form 4 filing provides the first public disclosure of the CEO's recent share sale, offering fresh data for valuation models.
Market read
Insider transaction adds new information for traders monitoring ARTV, but the modest size limits broader market relevance.
What to watch
The CEO retains a large stake and the company may be preparing for upcoming clinical milestones.
Background
Artiva Biotherapeutics (ARTV) is a Nasdaq‑listed biotech developing therapies for liver diseases.
Ticker impact
CEO Aslan Fred sold 61,888 shares for $690,391, reducing his stake to 1,473,194 shares.
Potential short‑term pressure on ARTV price, likely limited to a few percent.
The sale represents less than 5% of the insider's total holdings and is under $1M, so market reaction is expected to be muted.
Market effects
Minimal impact on the broader biotech sector; similar insider sales are common.
No significant regional effect.
Limited to investors tracking ARTV.
Counterpoint
The sale could be a routine liquidity move rather than a negative signal.
Key entities
- CompanyArtiva Biotherapeutics, Inc.
Biotech firm developing liver disease treatments.
- ExecutiveAslan Fred
Chief Executive Officer of Artiva Biotherapeutics.